"Boehringer Ingelheim is deeply committed to progressing science through Research & Development," said Dr. Manfred Haehl, Corporate Senior Vice President Medicine. "In 2007 the company invested 1.73 billion Euros in Research & Development, and added 400 new employees, bringing our total global headcount in Research & Development to 6,400."
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of 10.9 billion Euros while spending one fifth of net sales in its largest business segment Prescription Medicines on Research and Development.
For further information please visit http://www.boehringer-ingelheim.com
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document.
---------------------------------
(1) International Diabetes Federation. Diabetes Atlas. 3rd edn. Brussels: International Diabetes Federation, 2006.
(2) If approved by regulatory authorities, BIBW 2992 is planned to be marketed under the trade name TOVOK(R).
(3) If approved by regulatory authorities, BIBF 1120 is planned to be marketed under the trade name VARGATEF(R).
Contact: Julia Meyer-Kleinmann, Head of Science & Technology Communications, Boehringer Ingelheim GmbH, Tel.: +49-6132-77-8271, Email: press@boehringer-ingelheim.com
